← Human Trials & Peer-Reviewed Studies

GLUCAGON-LIKE PEPTIDE-1 AFFECTS TASTE PERCEPTION DIFFERENTLY IN WOMEN: A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER STUDY.

Plain-language guide to PMID 31819319 (2019): double-blind randomized controlled trial of Glucagon.

Key Facts

PMID
31819319
Journal
Acta clinica Croatica
Year
2019
Study type
Randomized Controlled Trial
Authors
Baretić M et al. (5 authors)
DOI
10.20471/acc.2019.58.02.06

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

The aim of the study was to find out how gut hormone glucagon-like peptide-1 (GLP-1) influences taste preference.

Why It Was Studied

Gastrointestinal tract is an important connector between food intake and body weight, it senses basic tastes in a similar manner as the tongue.

At the end of infusion, participants chose food preferences from illustrations of food types representing 5 tastes.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Fourteen healthy participants (six male and eight female) were included in this double-blind, placebo-controlled crossover study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Glucagon.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

What Was Measured

Gastrointestinal tract is an important connector between food intake and body weight, it senses basic tastes in a similar manner as the tongue.

Topics PubMed links to this paper include Food Preferences, Glucagon-Like Peptide 1, Sex Factors, Taste and Taste Perception.

The authors tagged it with the keywords Cross-over studies and Double-blind method.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

The publication is from 2019 (Acta clinica Croatica), a journal based in Croatia.

More context: the Glucagon compound page, all human trials.

Our Notes on the Compound

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.